Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 9;13:6762. doi: 10.1038/s41467-022-34434-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — a The relative mRNA m⁶A level in murine hearts with or without I/R remodeling (n = 4/group). b Representative western blot and statistical data of METTL14 expression levels in the I/R 3w mouse hearts compared with sham surgery (n = 6 mice/group). c Schedule of virus injection and myocardial I/R injury-induced mouse pathological cardiac remodeling model establishment. d Representative western blot and statistical data of METTL14 expression levels in mouse hearts treated as indicated (n = 6 mice/group). e The relative mRNA m⁶A level in I/R 3w murine hearts infected with METTL14 knockdown or scrambled control AAV9 (n = 4/group). f Representative echocardiographic images and left ventricular ejection fraction (EF), ventricular fractional shortening (FS) of mice injected with AAV9-cTnT-shMETTL14 or scrambled control at day 21 after I/R surgery (n = 7, 8, 14, and 10 mice, respectively). g Representative images of H&E staining (Top, scale bar: 50 μm) and WGA staining (Bottom, scale bar: 20 μm). h Quantitative analysis of cross-sectional area of cardiac cells stained with WGA of ventricular myocardial cells in mouse hearts treated as indicated (n = 7, 8, 14, and 10 mice, respectively). i Representative images of Masson’s trichrome staining and quantification of fibrotic area (%) in mouse hearts treated as indicated (n = 7, 8, 14, and 10 mice, respectively). Scale bar: 50 μm. j qPCR analysis of Anp, Bnp, β-Mhc, and α-Sma mRNA levels in mouse hearts treated as indicated (n = 7, 8, 14, and 10 mice, respectively). I/R, ischemia-reperfusion. Echo, echocardiography. AAV9-cTnT-shScr, cardiac-specific troponin-T promoter-driven Scramble AAV9; AAV9-cTnT-shMETTL14, cardiac-specific troponin-T promoter-driven METTL14 knockdown AAV9; WGA, Wheat Germ Agglutinin; H&E, Hematoxylin & eosin. All data are expressed as means ± SD. d, f, h, i, j Two-way ANOVA followed by Tukey’s post hoc test; a, b, e independent-sample t-test, two-sided. Source data are provided as a Source Data file.